NASDAQ: AKANAkanda Corp Stock
$2.37+0.16 (+7.24%)
Updated Oct 14, 2025
AKAN Price
$2.37
Fair Value Price
N/A
Market Cap
$1.73M
52 Week Low
$2.11
52 Week High
$9.29
P/E
0.54x
P/B
0.52x
P/S
8.44x
PEG
N/A
Dividend Yield
N/A
Revenue
$359.66k
Earnings
-$2.23M
Gross Margin
9.6%
Operating Margin
-619.14%
Profit Margin
-619.5%
Debt to Equity
0.88
Operating Cash Flow
-$2M
Beta
1.15
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
AKAN Overview
Akanda Corp. cultivates, manufactures, and distributes cannabis products in the U.K. and internationally. It suppies cannabis and cannabis-based medical and wellness products. The Company's subsidiaries include Bophelo Bio Science and Wellness (Pty) Limited, Canmart Limited, Bophelo Holdings Limited, Cannahealth Limited and Holigen Limited. Akanda was incorporated in 2021 and is headquartered in New Romney, U.K.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine AKAN's potential to beat the market
- AKAN doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical
Industry Rating
B
AKAN
RankedUnranked of 59
RankedUnranked of 59
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $9.72 | A | |
| $88.74 | A | |
| $8.19 | A |
Be the first to know about important AKAN news, forecast changes, insider trades & much more!
AKAN News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how AKAN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AKAN is good value based on its earnings relative to its share price (0.54x), compared to the US market average (36.87x)
P/E vs Market Valuation
AKAN is good value based on its earnings relative to its share price (0.54x), compared to the US Drug Manufacturers - Specialty & Generic industry average (-41.57x)
P/E vs Industry Valuation
AKAN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
There are 30 more AKAN due diligence checks available for Premium users.
Valuation
AKAN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0.54x
Industry
-41.57x
Market
36.87x
AKAN is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
AKAN is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
AKAN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.52x
Industry
2.21x
AKAN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
AKAN's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
AKAN's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
AKAN's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$6.2M
Liabilities
$2.9M
Debt to equity
0.88
AKAN's short-term assets ($3.57M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AKAN's short-term assets ($3.57M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AKAN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
AKAN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
AKAN vs Pharmaceutical Stocks
Akanda Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.